Univariable and multivariable analysis of EFS in relation to PCR-determined IKZF1 status
| . | EFS . | OS . | ||||
|---|---|---|---|---|---|---|
| Events/N . | HR (95% CI) . | P . | Events/N . | HR (95% CI) . | P . | |
| All patients | ||||||
| WT | 191/339 | 1.00 | .64 | 164/339 | 1.00 | .36 |
| ΔIKZF1 | 54/98 | 0.93 (0.69, 1.26) | 44/98 | 0.86 (0.61-1.20) | ||
| WT | 191/339 | 1.00 | 164/339 | 1.00 | ||
| ΔIKZF1 DN (4-7) | 32/58 | 0.95 (0.65- 1.38) | .88 | 28/58 | 0.95 (0.64-1.43) | .47 |
| ΔIKZF1 LOF | 22/40 | 0.90 (0.58-1.40) | 16/40 | 0.73 (0.44-1.22) | ||
| BCR-ABL1− ALL | ||||||
| WT | 139/251 | 1.00 | .28 | 122/251 | 1.00 | .40 |
| ΔIKZF1 | 27/42 | 1.25 (0.83, 1.89) | 24/42 | 1.20 (0.78-1.87) | ||
| MVA: WT | 117/206 | 1.00 | .35 | 103/206 | 1.00 | .39 |
| MVA: ΔIKZF1 | 25/38 | 1.23 (0.80, 1.92) | 24/38 | 1.33 (0.82-1.68) | ||
| WT | 139/251 | 1.00 | .55 | 122/251 | 1.00 | .70 |
| ΔIKZF1 DN (4-7) | 15/24 | 1.21 (0.71-2.07) | 13/24 | 1.20 (0.68-2.12) | ||
| ΔIKZF1 LOF | 12/18 | 1.30 (0.72-2.35) | 11/18 | 1.21 (0.65-2.25) | ||
| MVA: WT | 117/206 | 1.00 | .54 | 103/206 | 1.00 | .43 |
| MVA: ΔIKZF1 DN (4-7) | 14/22 | 1.39 (0.79-2.45) | 13/22 | 1.48 (0.82-2.66) | ||
| MVA:ΔIKZF1 LOF | 11/16 | 1.07 (0.57-2.03) | 11/16 | 1.18 (0.62-2.24) | ||
| BCR-ABL1+ ALL | ||||||
| WT | 52/88 | 1.00 | .13 | 42/88 | 1.00 | .11 |
| ΔIKZF1(all BCR-ABL1+) | 27/56 | 0.70 (0.44, 1.11) | 20/56 | 0.65 (0.38-1.11) | ||
| p190 breakpoint | ||||||
| MVA: WT | 36/53 | 1.00 | .019 | 30/53 | 1.00 | .003 |
| MVA: ΔIKZF1 | 15/32 | 0.47 (0.25, 0.88) | 9/32 | 0.30 (0.14-0.66) | ||
| MVA: WT | 36/53 | 1.00 | 30/53 | 1.00 | ||
| MVA: ΔIKZF1 DN (4-7) | 9/19 | 0.44 (0.19-1.00) | .050 | 8/19 | 0.41 (0.17-0.8) | .044 |
| MVA: ΔIKZF1 LOF | 6/13 | 0.50 (0.21-1.20) | .012 | 1/13 | 0.10 (0.01-0.77) | .027 |
| p210 breakpoint | ||||||
| MVA: WT | 12/27 | 1.00 | .89 | 9/27 | 1.00 | .77 |
| MVA: ΔIKZF1 (p210 breakpoint) | 9/20 | 0.94 (0.39-2.27) | 8/20 | 1.16 (0.44-3.07) | ||
| MVA: WT | 12/27 | 1.00 | 9/27 | 1.00 | ||
| MVA: ΔIKZF1 DN (4-7) | 6/13 | 1.21 (0.44-3.29) | .71 | 5/13 | 1.23 (0.40-3.76) | .72 |
| MVA: ΔIKZF1 LOF | 3/7 | 0.65 (0.18-2.36) | .51 | 3/7 | 1.05 (0.28-3.96) | .95 |
| . | EFS . | OS . | ||||
|---|---|---|---|---|---|---|
| Events/N . | HR (95% CI) . | P . | Events/N . | HR (95% CI) . | P . | |
| All patients | ||||||
| WT | 191/339 | 1.00 | .64 | 164/339 | 1.00 | .36 |
| ΔIKZF1 | 54/98 | 0.93 (0.69, 1.26) | 44/98 | 0.86 (0.61-1.20) | ||
| WT | 191/339 | 1.00 | 164/339 | 1.00 | ||
| ΔIKZF1 DN (4-7) | 32/58 | 0.95 (0.65- 1.38) | .88 | 28/58 | 0.95 (0.64-1.43) | .47 |
| ΔIKZF1 LOF | 22/40 | 0.90 (0.58-1.40) | 16/40 | 0.73 (0.44-1.22) | ||
| BCR-ABL1− ALL | ||||||
| WT | 139/251 | 1.00 | .28 | 122/251 | 1.00 | .40 |
| ΔIKZF1 | 27/42 | 1.25 (0.83, 1.89) | 24/42 | 1.20 (0.78-1.87) | ||
| MVA: WT | 117/206 | 1.00 | .35 | 103/206 | 1.00 | .39 |
| MVA: ΔIKZF1 | 25/38 | 1.23 (0.80, 1.92) | 24/38 | 1.33 (0.82-1.68) | ||
| WT | 139/251 | 1.00 | .55 | 122/251 | 1.00 | .70 |
| ΔIKZF1 DN (4-7) | 15/24 | 1.21 (0.71-2.07) | 13/24 | 1.20 (0.68-2.12) | ||
| ΔIKZF1 LOF | 12/18 | 1.30 (0.72-2.35) | 11/18 | 1.21 (0.65-2.25) | ||
| MVA: WT | 117/206 | 1.00 | .54 | 103/206 | 1.00 | .43 |
| MVA: ΔIKZF1 DN (4-7) | 14/22 | 1.39 (0.79-2.45) | 13/22 | 1.48 (0.82-2.66) | ||
| MVA:ΔIKZF1 LOF | 11/16 | 1.07 (0.57-2.03) | 11/16 | 1.18 (0.62-2.24) | ||
| BCR-ABL1+ ALL | ||||||
| WT | 52/88 | 1.00 | .13 | 42/88 | 1.00 | .11 |
| ΔIKZF1(all BCR-ABL1+) | 27/56 | 0.70 (0.44, 1.11) | 20/56 | 0.65 (0.38-1.11) | ||
| p190 breakpoint | ||||||
| MVA: WT | 36/53 | 1.00 | .019 | 30/53 | 1.00 | .003 |
| MVA: ΔIKZF1 | 15/32 | 0.47 (0.25, 0.88) | 9/32 | 0.30 (0.14-0.66) | ||
| MVA: WT | 36/53 | 1.00 | 30/53 | 1.00 | ||
| MVA: ΔIKZF1 DN (4-7) | 9/19 | 0.44 (0.19-1.00) | .050 | 8/19 | 0.41 (0.17-0.8) | .044 |
| MVA: ΔIKZF1 LOF | 6/13 | 0.50 (0.21-1.20) | .012 | 1/13 | 0.10 (0.01-0.77) | .027 |
| p210 breakpoint | ||||||
| MVA: WT | 12/27 | 1.00 | .89 | 9/27 | 1.00 | .77 |
| MVA: ΔIKZF1 (p210 breakpoint) | 9/20 | 0.94 (0.39-2.27) | 8/20 | 1.16 (0.44-3.07) | ||
| MVA: WT | 12/27 | 1.00 | 9/27 | 1.00 | ||
| MVA: ΔIKZF1 DN (4-7) | 6/13 | 1.21 (0.44-3.29) | .71 | 5/13 | 1.23 (0.40-3.76) | .72 |
| MVA: ΔIKZF1 LOF | 3/7 | 0.65 (0.18-2.36) | .51 | 3/7 | 1.05 (0.28-3.96) | .95 |
Multivariable analyses are shown in italics. All MVA analyses include age, sex, ECOG, log WBC, and rituximab randomization. BCR-ABL1− models include genetic risk group (good, standard, or high); BCR-ABL1+ models also included breakpoint (p190 or p201) and an interaction term between IKZF1 and breakpoint (P values for interaction deleted/WT: EFS P = .22 and OS P = .036). The corresponding table for MLPA-determined IKZF1 status is shown as supplemental Table 2.
CI, confidence interval; MVA, multivariate analysis.